NovoCure reports preliminary FY2024 net revenues $605M (+19% YoY); Q4 $161M (+21%)

NovoCure Ltd

2024-FY EPS reported -$1.56 revenue$605,220,000

Preliminary FY2024 net revenues $605.2M (+19% YoY); Q4 $161.3M (+21% YoY).
Active patients globally: 4,126 total on TTFields; 4,077 Optune Gio; 52 Optune Lua prescriptions for NSCLC.
Cash, cash equivalents and short-term investments $959.9M as of Dec 31, 2024.
FDA approved Optune Lua for metastatic NSCLC in Oct 2024; Phase 3 PANOVA-3 trial met primary endpoint in pancreatic cancer.
FY2025 revenue growth expected to align with Optune Gio active patient growth; US prior-period claims added $8.3M in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.